Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hengli (botulinum toxin type A) for benign masseter hypertrophy
CTR20220615Phase 3Completed
- Sponsor
- Lanzhou Biotechnique Development
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A in masseter hypertrophy, sponsored by Lanzhou Biotechnique Development. Started Mar 2022; status: completed.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
masseter hypertrophy
Beyond the preview
Go deeper on CTR20220615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220615.